This content is machine translated ACC 2018 Success story of PCSK9 inhibition continues For the first time after the highly acclaimed FOURIER trial, a PCSK9 inhibitor now also shows a mortality benefit in secondary prevention. The product in question is alirocumab. Experts are…
